Scientists investigating how the human immune system defends against malaria have uncovered a rare phenomenon: antibodies working together to bind to a vulnerable spot on the parasite.
Scientists at The Scripps Research Institute have discovered a new aspect of the flu virus and how it interacts with antibodies in the lungs.
“This study is a good example of a host/pathogen arms race playing out in real-time–this time with the host a likely winner.”
The Skaggs Graduate School of Chemical and Biological Sciences at The Scripps Research Institute is ranked among the top ten in the nation according to a recent survey by U.S. News & World Report.
Researchers at The Scripps Research Institute (TSRI) have designed a new molecule-building method that uses sulfones as partners for cross-coupling reactions, or the joining of two distinct chemical entities in a programmed fashion aided by a catalyst.
Scientists at The Scripps Research Institute (TSRI) have now shown a path to developing treatments for disease subtype CMT2D.
‘This study identifies the missing link between Lewy bodies and the type of damage that’s been observed in neurons affected by Parkinson’s.”
The breakthrough may expand research on the roles of glycans in human diseases, including cancers.
These new areas of interest belong to the so-called “non-coding” genome–the 98 percent of the genome that doesn’t directly code for proteins but instead regulates how key proteins are produced.
“These results lay the groundwork for the next steps toward FDA approval,” says John Griffin, PhD, professor at TSRI, whose team invented 3K3A-APC.